I have no doubt in my mind that it's the westar clients stacking...

I have no doubt in my mind that it's the westar clients stacking the offer, and that is what pi$$e$ me off to no end. similarly to the $2M CR to "sophisticated investors" @ 0.6c in 2016...kept a lid on the share price until about a month before 2b trials were announced...the CR this time around was 4 X bigger...what does that tell you.

I've been involved in the markets long enough to understand how the broking industry works and it doesn't give a $h!t about anyone, not their clients or their corporate mandates, only lining their own pockets.

and what exactly will westar now be mandated to do? I mean as far as the recent detail-lite announcements have indicated, dimerix will be purely focused on commencing the fsgs & DN trials...unless westar have a team of highly specialized kidney specialists and scientists hidden somewhere in the basement or their gimp-room, what good is it to have an additional

corporate advisory ​

expense on the payroll? I though that was Alsop & Williams job?!?

if Dimerix are reading this, tell your corporate advisors to stop selling stock and get those oversubscriptions to bid the stock on market